AUTX-703

· Auron Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AUTX-703, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS [Phase 1]